Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Prana – ANA Abstract Submission NLP

October 17, 2016August 16, 2022 Alterity Therapeutics

final-ana-abstract-submission-nlp-4-8-16

2016

Post navigation

New data from Reach2HD trial presented at American Neurological Association Annual Meeting

Related Posts

Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

March 8, 2023May 23, 2023

Prana Announces that New York Academy of Sciences eBriefing available online

July 17, 2013August 16, 2022

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

October 19, 2021August 16, 2022

Recent Posts

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
Alterity to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065